We have located links that may give you full text access.
Effect of lipid-based nutrient supplements on micronutrient status and hemoglobin among children with stunting: secondary analysis of a randomized, controlled trial in Uganda.
American Journal of Clinical Nutrition 2024 January 25
BACKGROUND: Micronutrient deficiencies and anemia are widespread among children with stunting.
OBJECTIVE: We assessed the effects of lipid-based nutrient supplements (LNS) containing milk protein (MP) and/or whey permeate (WP) on micronutrient status and hemoglobin (Hb) among children with stunting.
DESIGN: This was a secondary analysis of a randomized, controlled trial. Children 12-59-month-old with stunting were randomized to LNS (100g/d) with milk or soy protein and WP or maltodextrin for 12 weeks, or no supplement. Hb, serum ferritin (S-FE), serum soluble transferrin receptor (S-TfR), plasma cobalamin (P-Cob), plasma methylmalonic acid (P-MMA), plasma folate (P-Fol) and serum retinol binding protein (S-RBP) were measured at inclusion and at 12 weeks. Data was analyzed using linear and logistic mixed-effects models.
RESULTS: Among 750 children, mean ±SD age was 32 ±11.7 months, 45% (n=338) were female and 98% (n=736) completed follow-up. LNS, compared to no supplementation, resulted in 43% (95% CI: 28, 60) greater increase in inflammation-corrected-S-FE (S-FEci), 2.4 (95% CI: 1.2, 3.5) mg/L greater decline in S-TfR, 138 (95% CI: 111, 164) pmol/L greater increase in P-Cob, 33% (95% CI: 27, 39) reduction in P-MMA, and 8.5 (95% CI: 6.6, 10.3) nmol/L greater increase in P-Fol. There was no effect of LNS on S-RBP. Lactation modified the effect of LNS on markers of cobalamin status, reflecting improved status among non-breastfed and no effects among breastfed children. LNS increased Hb by 3.8 (95% CI: 1.7, 6.0) g/L and reduced the odds of anemia by 55% (OR 0.45, 95% CI: 0.29, 0.70). MP compared to soy protein increased S-FEci by 14% (95% CI: 3, 26).
CONCLUSIONS: LNS supplementation increased Hb and improved iron, cobalamin and folate status, but not vitamin A status among children with stunting. LNS should be considered for children with stunting. (www.isrctn.com: ISRCTN13093195) CLINICAL TRIAL REGISTRY: ISRCTN 13093195, website: https://www.isrctn.com/ISRCTN13093195.
OBJECTIVE: We assessed the effects of lipid-based nutrient supplements (LNS) containing milk protein (MP) and/or whey permeate (WP) on micronutrient status and hemoglobin (Hb) among children with stunting.
DESIGN: This was a secondary analysis of a randomized, controlled trial. Children 12-59-month-old with stunting were randomized to LNS (100g/d) with milk or soy protein and WP or maltodextrin for 12 weeks, or no supplement. Hb, serum ferritin (S-FE), serum soluble transferrin receptor (S-TfR), plasma cobalamin (P-Cob), plasma methylmalonic acid (P-MMA), plasma folate (P-Fol) and serum retinol binding protein (S-RBP) were measured at inclusion and at 12 weeks. Data was analyzed using linear and logistic mixed-effects models.
RESULTS: Among 750 children, mean ±SD age was 32 ±11.7 months, 45% (n=338) were female and 98% (n=736) completed follow-up. LNS, compared to no supplementation, resulted in 43% (95% CI: 28, 60) greater increase in inflammation-corrected-S-FE (S-FEci), 2.4 (95% CI: 1.2, 3.5) mg/L greater decline in S-TfR, 138 (95% CI: 111, 164) pmol/L greater increase in P-Cob, 33% (95% CI: 27, 39) reduction in P-MMA, and 8.5 (95% CI: 6.6, 10.3) nmol/L greater increase in P-Fol. There was no effect of LNS on S-RBP. Lactation modified the effect of LNS on markers of cobalamin status, reflecting improved status among non-breastfed and no effects among breastfed children. LNS increased Hb by 3.8 (95% CI: 1.7, 6.0) g/L and reduced the odds of anemia by 55% (OR 0.45, 95% CI: 0.29, 0.70). MP compared to soy protein increased S-FEci by 14% (95% CI: 3, 26).
CONCLUSIONS: LNS supplementation increased Hb and improved iron, cobalamin and folate status, but not vitamin A status among children with stunting. LNS should be considered for children with stunting. (www.isrctn.com: ISRCTN13093195) CLINICAL TRIAL REGISTRY: ISRCTN 13093195, website: https://www.isrctn.com/ISRCTN13093195.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices 
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app